Correlation between tumor necrosis factor-alpha and D-dimer levels in non-small cell lung cancer patients.

[1]  Rui Li,et al.  Analysis of the immunological microenvironment at the tumor site in patients with non-small cell lung cancer , 2003, Langenbeck's Archives of Surgery.

[2]  D. Stojanovic,et al.  Cytokines in Patients with Lung Cancer , 2003, Scandinavian journal of immunology.

[3]  F. Santolaria,et al.  Leptin role in advanced lung cancer. A mediator of the acute phase response or a marker of the status of nutrition? , 2002, Cytokine.

[4]  C. Miki,et al.  Expression of tissue factor and vascular endothelial growth factor is associated with angiogenesis in colorectal cancer , 2002, American journal of hematology.

[5]  D. Ferrigno,et al.  Prognostic significance of blood coagulation tests in lung cancer. , 2001, The European respiratory journal.

[6]  Marina Heiden,et al.  Tissue factor is the only activator of coagulation in cultured human lung cancer cells. , 2001, Lung cancer.

[7]  Alberto Mantovani,et al.  Inflammation and cancer: back to Virchow? , 2001, The Lancet.

[8]  M. Shoji,et al.  The Role of the Hemostatic System in Tumor Growth, Metastasis, and Angiogenesis: Tissue factor is a Bifunctional Molecule Capable of Inducing Both Fibrin Deposition and Angiogenesis in Cancer , 2001, International journal of hematology.

[9]  G. Hawson,et al.  Impact of the fibrinolytic enzyme system on prognosis and survival associated with non-small cell lung carcinoma , 2001, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[10]  K. Arimura,et al.  Serum levels of vascular endothelial growth factor dependent on the stage progression of lung cancer. , 2000, Chest.

[11]  G. Hawson,et al.  Alterations to the fibrinolytic enzyme system in patients with non-small cell lung carcinoma. , 1999, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[12]  G. Davı̀,et al.  Enhanced thromboxane biosynthesis in patients with chronic obstructive pulmonary disease. The Chronic Obstructive Bronchitis and Haemostasis Study Group. , 1997, American journal of respiratory and critical care medicine.

[13]  T. van der Poll,et al.  Cytokines: Triggers of Clinical Thrombotic Disease , 1997, Thrombosis and Haemostasis.

[14]  M. Yoshida,et al.  Prognostic significance of plasma D-dimer levels in patients with lung cancer. , 1997, Thorax.

[15]  T. van der Poll,et al.  Effect of a recombinant dimeric tumor necrosis factor receptor on inflammatory responses to intravenous endotoxin in normal humans. , 1997, Blood.

[16]  T. van der Poll,et al.  Interleukin-6 Stimulates Coagulation, not Fibrinolysis, in Humans , 1996, Thrombosis and Haemostasis.

[17]  A. Girbes,et al.  Effects of hyperthermic isolated limb perfusion with recombinant tumor necrosis factor alpha and melphalan on the human fibrinolytic system. , 1996, Cancer research.

[18]  S. Basili,et al.  Hypercoagulability State in Patients with Chronic Obstructive Pulmonary Disease , 1994, Thrombosis and Haemostasis.

[19]  T. van der Poll,et al.  Differential effects of anti-tumor necrosis factor monoclonal antibodies on systemic inflammatory responses in experimental endotoxemia in chimpanzees. , 1994, Blood.

[20]  R. Seitz,et al.  Activation of coagulation and fibrinolysis in patients with lung cancer: relation to tumour stage and prognosis , 1993, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[21]  E. Gabazza,et al.  Coagulation‐fibrinolysis system and markers of collagen metabolism in lung cancer , 1992, Cancer.

[22]  S. Barni,et al.  Tumor necrosis factor in solid tumors: increased blood levels in the metastatic disease. , 1992, Journal of biological regulators and homeostatic agents.

[23]  T. van der Poll,et al.  Fibrinolytic response to tumor necrosis factor in healthy subjects , 1991, The Journal of experimental medicine.

[24]  H. Büller,et al.  Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways , 1990 .

[25]  O. Skjønsberg,et al.  Local activation of the coagulation and fibrinolysis systems in lung disease. , 1990, Thrombosis research.

[26]  F. Guadagni,et al.  Vascular endothelial growth factor (VEGF-A) plasma levels in non-small cell lung cancer: relationship with coagulation and platelet activation markers , 2003, Thrombosis and Haemostasis.

[27]  J. V. D. van der Meer,et al.  The Role of Cytokines in Activation of Coagulation and Fibrinolysis in Dengue Shock Syndrome , 2002, Thrombosis and Haemostasis.

[28]  G. Labbadia,et al.  Soluble P-selectin as a marker of platelet hyperactivity in patients with chronic obstructive pulmonary disease. , 2000, Journal of investigative medicine : the official publication of the American Federation for Clinical Research.

[29]  E. Gabazza,et al.  Evaluating prethrombotic state in lung cancer using molecular markers. , 1993, Chest.

[30]  J. V. van Wersch,et al.  Coagulation/fibrinolysis balance and lung cancer. , 1991, Haemostasis.

[31]  H. Büller,et al.  Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. , 1990, Blood.